Incyte Corporation: Breast Neoplasms trials
The registry lists 10 Breast Neoplasms studies with Incyte Corporation as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 8Phase 2 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedNCT02711137Phase 1/2Results posted
- An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced MalignanciesTerminatedNCT02431260Phase 1/2Results posted
- Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)TerminatedNCT02393248Phase 1/2Results posted
- A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast CancerTerminatedNCT02120417Phase 2Results posted
- Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1
- An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibActive, not recruitingNCT02955940Phase 2
- Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsCompletedNCT02646748Phase 1
- An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced MalignanciesTerminatedNCT01929941Phase 1
- Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast CancerTerminatedNCT01254136Phase 1/2
- Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast CancerTerminatedNCT00864175Phase 1/2